HVTN 908

Phase:Open Label
Principal Investigator(s):Erica Andersen-Nissen, PhD
Objective:HVTN 908 is a sub study of the HIV vaccine trial, HVTN 205. The purpose of this sub study is to better understand how a person's immune system responds to vaccines, particularly HIV vaccines. More specifically, researchers will determine whether early responses in the immune system help predict strong and long-lasting immunity.   Last updated May 25, 2022
Prevention Option(s):HIV Vaccine
Study Design:
Arms and Assigned Interventions
DescriptionA Participants receiving the JS7 DNA and MVA/HIV62 vaccinations in HVTN 205
Mode of Delivery
Official Code: NCT00908323
Trial Sponsors: NIAID (DAIDS ES 10806)
Start Date
End Date
July 1, 2009
July 1, 2012
Age range: 18 Years ↔ 50 Years
Population:Cisgender Men